PharmCo III ApS: Financial statements 2023
CVR: 41103647
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
PharmCo III ApS (CVR 41103647) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -29,175 and a net result of DKK 11,059,518 compared with DKK 12,142,196 the year before. Equity in the 2023 report amounted to DKK 61,399,531. The solvency ratio was 70.3%.
- Gross Profit
- DKK -29,175
- Profit/Loss
- DKK 11,059,518
- Equity
- DKK 61,399,531
- Total Assets
- DKK 87,332,951
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -29 t. | 11.1 mio. | 61.4 mio. | - |
| 2022 | - | -27 t. | 12.1 mio. | 50.6 mio. | - |
| 2021 | 0 | -26 t. | 20.5 mio. | 39 mio. | - |
| 2020 | - | -35 t. | 18.6 mio. | 18.2 mio. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
PharmCo III ApS has published its annual report for 2022. Gross profit came to DKK -27,100, and the net result was DKK 12,142,196.
About PharmCo III ApS
PharmCo III ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 2020. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Eli Wallin. The company is owned by Eli Wallin. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -33,000 and a net result of DKK 18,532,000 compared with DKK 13,877,698 the year before. Equity in the 2025 report amounted to DKK 100,696,000.